PINTEON THERAPEUTICS
Pinteon Therapeutics focuses on the discovery and development of breakthrough therapeutics targeting Pin1. Pin1 acts as a central regulator in cancer development and growth as well as a number of other disease areas including CNS and autoimmune diseases. By inhibiting or activating Pin1, Pinteon will normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications. Pinteon Therapeutics was founded in 2014 and is headquartered in Newton, Massachusetts.
PINTEON THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.pinteon.com
Total Employee:
1+
Status:
Active
Contact:
917-607-0015
Email Addresses:
[email protected]
Total Funding:
51.6 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Organization Schema Sitelinks Search Box JsDelivr
Similar Organizations
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Vega Therapeutics
Vega Therapeutics is a biotechnology startup in the clinical stages of creating innovative treatments for uncommon blood disorders.
Current Employees Featured
Founder
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Pinteon Therapeutics
Official Site Inspections
http://www.pinteon.com Semrush global rank: 11.52 M Semrush visits lastest month: 156
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pinteon Therapeutics"
Pinteon Therapeutics - Crunchbase Company Profile & Funding
Pinteon Therapeutics focuses on the discovery and development of breakthrough therapeutics targeting Pin1. Pin1 acts as a central regulator in cancer development and growth as well as a …See details»
Pinteon Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Pinteon Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 6 news, and 1 literature, Drug:PNT-001. Biomedical products. ... the results of …See details»
Pinteon Therapeutics - LinkedIn
Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of ...See details»
Pinteon Therapeutics - Craft
Pinteon Therapeutics is a company that develops cancer therapeutics drugs intended to cure cis-trans isomerase. Its drugs are based out of biotechnological compounds focused on the …See details»
Pinteon Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Pinteon Therapeutics, Inc. of Newton, MA. Get the latest business insights from Dun & Bradstreet.See details»
Pinteon Therapeutics - VentureRadar
Pinteon Therapeutics aims to protect and preserve brain function in patients suffering from tauopathies. Millions of people around the world are living with diseases such as traumatic …See details»
Pinteon Therapeutics Announces Scientific Advisory Board for …
Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of …See details»
Pinteon Therapeutics Company Profile 2024: Valuation, Funding ...
Pinteon Therapeutics General Information Description. Developer of a novel antibody intended to maintain the brain health of the patients. The company's antibody interrupts the spread of toxic …See details»
Pinteon Therapeutics - Funding, Financials, Valuation & Investors
Pinteon Therapeutics is funded by Morningside Venture Investments. Pinteon Therapeutics has a post-money valuation in the range of $50M to $100M as of Oct 31, 2019 , according to PrivCo …See details»
Pinteon Therapeutics - Contacts, Employees, Board Members
Organization. Pinteon Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Contacts 2. …See details»
Pinteon Therapeutics Announces Scientific Advisory Board for …
May 6, 2020 Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a …See details»
Pinteon Therapeutics Announces Upcoming Scientific Presentations
Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of …See details»
Cambridge Startup Targets Alzheimer's With A New Approach To …
Oct 31, 2019 Pinteon was founded in 2014, when Morningside purchased a license to technology developed by Kun Ping Lu at Beth Israel Deaconess Medical Center, according to …See details»
Pinteon Therapeutics - Updates, News, Events, Signals & Triggers
Pinteon Therapeutics is a biotechnology company advancing clinical studies of a novel antibody.See details»
PNT001 - ALZFORUM
Jun 28, 2024 In September 2019, Pinteon began a Phase 1 safety and tolerability study of PNT001 in healthy adults. In the trial, 49 people received single doses of 33, 100, 300, 900, …See details»
Pinteon Therapeutics Announces Upcoming Scientific Presentations
Jan 28, 2021 Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a …See details»
Pinteon Therapeutics Announces First Patient Dosed in Phase 1 …
Apr 6, 2021 Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a …See details»
Series B - Pinteon Therapeutics - 2022-01-11 - Crunchbase
Jan 11, 2022 Pinteon Therapeutics raised $28085713 on 2022-01-11 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. ... Funding Round. Series B - Pinteon …See details»
Preclinical characterization and IND‐enabling safety studies for …
Apr 1, 2023 The studies reported in this manuscript were supported by Pinteon Therapeutics, Inc. CONFLICT OF INTEREST STATEMENT. Lee Goldstein and Kurt R. Brunden received …See details»
Pinteon Therapeutics - Tech Stack, Apps, Patents & Trademarks
Pinteon Therapeutics is actively using 6 technologies for its website, according to BuiltWith. These include SPF , Euro , and Microsoft Exchange Online . Website Tech Stack by BuiltWithSee details»